This strategy, if adopted at the therapeutic level, simplifies the current approach aiming to block EphB4 cancer-promoting effects through inhibitor compounds requiring membrane translocation towards intracellular targeting of the EphB4 RTK activity. The gene discussed is EPHB4; the disease is cancer.